Opinion|Videos|November 17, 2026

Gedatolisib plus darolutamide: Early findings in mCRPC

Fact checked by: Hannah Clarke

Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.

In this video, Adam Sharp, PhD, BM, MRCP, BSc, discusses the rationale, design, and preliminary findings from a phase 1/2 study (NCT06190899) evaluating the combination of gedatolisib and darolutamide (Nubeqa) in patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed on androgen receptor pathway inhibitor (ARPI) therapy. These data were presented at the 2026 European Society for Medical Oncology Annual Congress in Madrid, Spain.1

Sharp is the leader of the translational therapeutics team and honorary consultant medical oncologist at The Royal Marsden NHS Foundation Trust and the Institute of Cancer Research.

Sharp explains the rationale for combining gedatolisib, a pan-PI3K/mTOR inhibitor, with darolutamide, an androgen receptor pathway inhibitor, based on the reciprocal interactions between androgen receptor signaling and the PI3K-mTOR pathway in prostate cancer. Inhibiting one pathway can activate the other through compensatory feedback mechanisms, providing a rationale for simultaneously targeting both pathways to potentially overcome adaptive resistance and improve treatment outcomes.

The ongoing, open-label, multicenter phase 1/2 study is evaluating the safety, tolerability, and antitumor activity of gedatolisib plus darolutamide in patients with mCRPC following progression on ARPI therapy. At ESMO 2026, investigators presented phase 1 dose-escalation findings from 45 patients treated across 3 gedatolisib dose cohorts (120 mg, 180 mg, and 240 mg).

The combination demonstrated a manageable safety profile, with 7 patients (16%) experiencing grade 3 treatment-related adverse events and no grade 4 treatment-related adverse events, treatment-related discontinuations, or treatment-related deaths. Confirmed PSA50 responses were observed in 26.7% of patients overall, with a median radiographic progression-free survival (rPFS) of 9.1 months. Among patients with prior abiraterone exposure, the PSA50 response rate was 40.9% and median rPFS was 15.7 months.

Sharp also discusses preliminary evidence of antitumor activity across different PTEN tumor status groups, noting that responses were observed in both PTEN-loss and PTEN-intact tumors. He emphasizes that these findings are early and that additional investigation will be needed to better characterize the combination's activity and determine its potential role in the mCRPC treatment landscape.

REFERENCE
1. Sharp A, de Bono K, Gonzalez BM, et al. A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC). Presented at: 2026 European Society for Medical Oncology Congress. October 23-27, 2026. Madrid, Spain. Poster 2237P


Related to this article